Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Day One Biopharmaceuticals, Inc. (DAWN) had Receiveable Turnover of 9.45 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$131.16M |
|
$-95.50M |
|
$5.28M |
|
$125.88M |
|
$348.43M |
|
$-217.27M |
|
$128.92M |
|
$-88.35M |
|
$-88.35M |
|
$-95.50M |
|
$-95.50M |
|
$-95.50M |
|
$-95.50M |
|
$-217.27M |
|
$-215.24M |
|
93.23M |
|
93.23M |
|
$-1.02 |
|
$-1.02 |
|
| Balance Sheet Financials | |
$562.33M |
|
$2.29M |
|
$20.46M |
|
$582.79M |
|
$73.45M |
|
-- |
|
$6.59M |
|
$80.04M |
|
$502.75M |
|
$487.12M |
|
$502.75M |
|
101.12M |
|
| Cash Flow Statement Financials | |
$-78.11M |
|
$-230.99M |
|
$203.29M |
|
$230.78M |
|
$124.97M |
|
$-105.82M |
|
$48.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
95.98% |
|
-165.65% |
|
-165.65% |
|
-164.10% |
|
-67.36% |
|
-72.81% |
|
$-80.28M |
|
-- |
|
-- |
|
-- |
|
0.23 |
|
1.59 |
|
|
Receiveable Turnover |
9.45 |
38.61 |
|
-18.99% |
|
-19.60% |
|
-16.39% |
|
-18.99% |
|
$4.97 |
|
$-0.86 |
|
$-0.84 |
|